Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
*Author to whom correspondence should be addressed.
Academic Editor: Stephan Segerer
Natural killer (NK) cells are innate immune cells that have long been known to be involved in the recognition and lysis of tumor cells. Despite significant gains in our understanding of the mechanisms that regulate NK cell function, the development of successful NK cell-based therapies has not yet been achieved. However, recent advances in our ability to modulate NK receptor signals and the sensitivity of tumor cells to NK cell-mediated lysis have led to a number of clinical trials testing novel methods to enhance NK cytotoxicity against cancer. Here, we present an overview of current therapies.